SMPD2 and heart failure: Diaphragm weakness and decreased ejection fraction in rats with heart failure caused by myocardial infarction are ameliorated in the context of reduced levels of neutral sphingomyelinase or lowered neutral sphingomyelinase activity by shRNA or a pharmacological inhibitor (GW4869) [62].